May 6, 2024 10:49 AM EDT
Financing
Startups

As­traZeneca-al­lied Ec­co­gene tar­gets ear­ly 2025 Nas­daq IPO with mul­ti­ple NASH can­di­dates

Kyle LaHucik

Senior Reporter

Ec­co­gene, a Boston and Shang­hai biotech work­ing on an oral GLP-1 can­di­date with As­traZeneca, is con­sid­er­ing an ini­tial pub­lic of­fer­ing ear­ly next year, CEO Jingye …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times